Covid19 Clinical Trial - Corticosteroids in Severe COVID-19

Status Completed

Clinical Trial Summary

Brief Summary: Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome in coronavirus-2 (SARS-CoV-2) infection are recommended by several guidelines. In the very beginning of SARS-CoV-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of acute respiratory distress syndrome (ARDS). But recently after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working group, routine administration of systemic corticosteroids was revisited. However, there is an ongoing debate regarding evidence supporting the dose, type of administration (bolus vs. continuous infusion), timing and type of corticosteroids. Ongoing randomized controlled trials (RCTs) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. Due to the dynamics of COVID-19 surges and rapid issuing of official recommendations, daily clinical practice of systemic corticosteroids administration can vary. An electronic evaluation form containing 20 questions will be sent to European Society of Intensive Care (ESICM) and European Society of Anaesthesiology and Intensive Care (ESAIC) members. Participants will be asked to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS.

Clinical Trial Description

Brief Summary: Administration of systemic corticosteroids for patients with severe forms of SARS-CoV-2 infection are recommended by several guidelines. In the very beginning of SARS-CoV-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of ARDS. But recently after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of WHO working group, routine administration of systemic corticosteroids was revisited. However, there is an ongoing debate regarding evidence supporting the dose, type of administration (bolus vs. continuous infusion), timing and type of corticosteroids. Ongoing RCTs (Randomized Clinical Trials) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. Due to the dynamics of COVID-19 surges and rapid issuing of official recommendations, daily clinical practice of systemic corticosteroids administration can vary. An electronic evaluation form containing 20 questions will be sent to European Society of Intensive Care (ESICM) European Society of Anaesthesiology and Intensive Care (ESAIC) members. Participants will be asked to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04866082
Study type	Observational
Source	Brno University Hospital
Contact
Status	Completed
Phase
Start date	May 30, 2021
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05175833` - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19	Phase 2
Recruiting	`NCT05256511` - COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Active, not recruiting	`NCT04918901` - Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Recruiting	`NCT05233605` - Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Not yet recruiting	`NCT04613986` - Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19	N/A
Recruiting	`NCT05447013` - Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients	Phase 1/Phase 2
Completed	`NCT04733833` - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19	Phase 2
Recruiting	`NCT04712344` - Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)	Phase 2
Terminated	`NCT04713176` - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients	Phase 3
Recruiting	`NCT04648410` - Corticosteroids in Severe COVID-19(ASAP-C Study)
Enrolling by invitation	`NCT06235866` - Risk Identification of Long-term Complications
Recruiting	`NCT05254990` - Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Phase 3
Completed	`NCT05596617` - Safety and Efficacy of Medications COVID-19	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study) — ASAPESICMESAIC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms